Leber congenital amaurosis 17

disease
On this page

Also known as GDF6 Leber congenital amaurosisLCA17Leber congenital amaurosis caused by mutation in GDF6Leber congenital amaurosis type 17

Summary

Leber congenital amaurosis 17 (MONDO:0014145) is a disease with 2 cohort genes.

At a glance

  • Cohort genes: 2
  • ClinVar variants: 390

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameLeber congenital amaurosis 17
Mondo IDMONDO:0014145
OMIM615360
DOIDDOID:0110217
UMLSC3715164
MedGen811616
GARD0015950
Is cancer (heuristic)no

Also known as: GDF6 Leber congenital amaurosis · LCA17 · Leber congenital amaurosis 17 · Leber congenital amaurosis caused by mutation in GDF6 · Leber congenital amaurosis type 17

Data availability: 390 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disordercongenital nervous system disorderLeber congenital amaurosisLeber congenital amaurosis 17

Related subtypes (20): retinal aplasia, Leber congenital amaurosis 1, Leber congenital amaurosis 2, Leber congenital amaurosis 3, Leber congenital amaurosis 4, Leber congenital amaurosis 5, Leber congenital amaurosis 9, Leber congenital amaurosis 12, Leber congenital amaurosis 10, Leber congenital amaurosis 13, Leber congenital amaurosis 14, Leber congenital amaurosis 6, Leber congenital amaurosis 7, Leber congenital amaurosis 8, Leber congenital amaurosis 11, Leber congenital amaurosis 15, Leber congenital amaurosis 16, Leber congenital amaurosis 19, Leber congenital amaurosis with early-onset deafness, Leber congenital amaurosis 18

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

390 retrieved; paginated sample, class counts are floors:

197 uncertain significance, 148 likely benign, 22 conflicting classifications of pathogenicity, 15 benign, 7 benign/likely benign, 1 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
60533NM_001001557.4(GDF6):c.876G>Y (p.Glu292Asp)GDF6Pathogenicno assertion criteria provided
1002016NM_001001557.4(GDF6):c.536C>A (p.Pro179Gln)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1023649NM_001001557.4(GDF6):c.902A>G (p.Glu301Gly)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1094356NM_001001557.4(GDF6):c.407-3C>TGDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1400072NM_001001557.4(GDF6):c.923_928dup (p.306GA[3])GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1404300NM_001001557.4(GDF6):c.959C>G (p.Pro320Arg)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1938713NM_001001557.4(GDF6):c.219C>A (p.Asp73Glu)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1959955NM_001001557.4(GDF6):c.454G>A (p.Val152Met)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
286405NM_001001557.4(GDF6):c.725C>G (p.Ala242Gly)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
2927707NM_001001557.4(GDF6):c.625C>T (p.Pro209Ser)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
364042NM_001001557.4(GDF6):c.1304C>T (p.Ala435Val)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
364044NM_001001557.4(GDF6):c.957C>A (p.Ala319=)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
364047NM_001001557.4(GDF6):c.770C>T (p.Pro257Leu)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
60534NM_001001557.4(GDF6):c.169G>C (p.Asp57His)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
707560NM_001001557.4(GDF6):c.24C>G (p.Leu8=)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
707574NM_001001557.4(GDF6):c.112G>C (p.Gly38Arg)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
836995NM_001001557.4(GDF6):c.815C>T (p.Pro272Leu)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
8371NM_001001557.4(GDF6):c.746C>A (p.Ala249Glu)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
8372NM_001001557.4(GDF6):c.866T>C (p.Leu289Pro)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
8373NM_001001557.4(GDF6):c.1271A>G (p.Lys424Arg)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
863448NM_001001557.4(GDF6):c.322G>A (p.Ala108Thr)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
914077NM_001001557.4(GDF6):c.250G>A (p.Glu84Lys)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
914078NM_001001557.4(GDF6):c.18C>T (p.Val6=)GDF6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1001816NM_001001557.4(GDF6):c.1310A>G (p.Asn437Ser)GDF6Uncertain significancecriteria provided, single submitter
1002101NM_001001557.4(GDF6):c.896C>T (p.Ser299Leu)GDF6Uncertain significancecriteria provided, single submitter
1007576NM_001001557.4(GDF6):c.611C>T (p.Pro204Leu)GDF6Uncertain significancecriteria provided, single submitter
1008100NM_001001557.4(GDF6):c.377C>T (p.Thr126Met)GDF6Uncertain significancecriteria provided, multiple submitters, no conflicts
1008463NM_001001557.4(GDF6):c.272G>C (p.Arg91Pro)GDF6Uncertain significancecriteria provided, multiple submitters, no conflicts
1015372NM_001001557.4(GDF6):c.323C>A (p.Ala108Asp)GDF6Uncertain significancecriteria provided, single submitter
1026389NM_001001557.4(GDF6):c.1229T>G (p.Met410Arg)GDF6Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 8 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
GDF6SupportiveAutosomal dominantLeber congenital amaurosis8

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
GDF6Orphanet:2345Isolated Klippel-Feil syndrome
GDF6Orphanet:3237Multiple synostoses syndrome
GDF6Orphanet:65Leber congenital amaurosis
GDF6Orphanet:98938Colobomatous microphthalmia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
GDF6HGNC:4221ENSG00000156466Q6KF10Growth/differentiation factor 6gencc,clinvar
PLEKHF2HGNC:20757ENSG00000175895Q9H8W4Pleckstrin homology domain-containing family F member 2clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
GDF6Growth/differentiation factor 6Growth factor that controls proliferation and cellular differentiation in the retina and bone formation.
PLEKHF2Pleckstrin homology domain-containing family F member 2May play a role in early endosome fusion upstream of RAB5, hence regulating receptor trafficking and fluid-phase transport.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor14.1×0.455
Other/Unknown10.9×0.805

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
GDF6Other/UnknownnoTGF-b_propeptide, TGF-b_C, TGF-beta-like
PLEKHF2Transcription factornoZnf_FYVE, PH_domain, Znf_FYVE_PHD

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
placenta1
primordial germ cell in gonad1
ventricular zone1
oocyte1
secondary oocyte1
upper leg skin1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
GDF6104broadmarkerplacenta, primordial germ cell in gonad, ventricular zone
PLEKHF2268ubiquitousmarkersecondary oocyte, oocyte, upper leg skin

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PLEKHF21,324
GDF61,127

Structural data

PDB: 0 · AlphaFold-only: 2 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
PLEKHF2Q9H8W487.36
GDF6Q6KF1070.88

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 2 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
cell migration involved in metanephros development18426.0×0.002GDF6
retinal cell apoptotic process14213.0×0.002GDF6
epithelial cell migration1468.1×0.008GDF6
activin receptor signaling pathway1443.5×0.008GDF6
positive regulation of chondrocyte differentiation1401.2×0.008GDF6
positive regulation of p38MAPK cascade1312.1×0.009GDF6
metanephros development1255.3×0.009GDF6
positive regulation of SMAD protein signal transduction1191.5×0.009GDF6
endosome organization1187.2×0.009PLEKHF2
endosome to lysosome transport1168.5×0.009PLEKHF2
BMP signaling pathway1100.3×0.013GDF6
positive regulation of neuron differentiation199.1×0.013GDF6
fat cell differentiation190.6×0.014GDF6
protein transport121.9×0.051PLEKHF2
apoptotic process114.3×0.070GDF6
positive regulation of DNA-templated transcription114.0×0.070GDF6

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
GDF600
PLEKHF200

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2GDF6, PLEKHF2

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
GDF60
PLEKHF20

Clinical trials & evidence

Clinical trials

Clinical trials: 0.